Activation of the PI3K/AKT/mTOR signalling pathway has been shown in ALPS, thus providing a rationale for targeting this pathway with mTOR inhibitors as this lymphoproliferative disease is associated with malignancy [86,87]. The gene discussed is AKT1; the disease is autoimmune lymphoproliferative syndrome.